



Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/816,531
		Filing Date	23 March 2001
		First Named Inventor	DIETZSCHOLD, Bernhard
		Group Art Unit	1642
		Examiner Name	
Total Number of Pages in This Submission	5	Attorney Docket Number	DIE01-NP001

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Statement to Support Filing and Submission of Sequence Listing in CRF and Paper Form
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Janet B. Smith
Signature	
Date	July 27, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name	
Signature	
Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P
EXPRESS MAIL NO. ET601501092US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bernhard Dietzschold

Serial No.: 09/816,531

Filed: 03/23/2001

: Group Art Unit: 1642

: Examiner: Unknown

: Attorney Docket
DIE01-NP001

For: Genetically Engineered Rabies Recombinant Vaccine for Immunization of Stray Dogs
And Wildlife

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825.**

- (X) I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 C.F.R. §1.821(c) and (e)**, respectively are the same.
- () I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 C.F.R. §1.825(a)**, included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(d)**, contains identical data to that originally filed.



Respectfully submitted,

Janet B. Smith
Janet B. Smith
Registration No. 45,461
Agent for Applicant
THOMAS JEFFERSON UNIVERSITY
1020 Walnut Street – Suite 623
Philadelphia, PA 19107-5587
Telephone: (215-923-3613)
Facsimile: (215-503-2386)

Date: 7/27/01



07-30-01

H-A-

Secto#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.: DIE01-NP001

TITLE: Genetically Engineered Rabies Recombinant Vaccine for Immunization of
Stray Dogs And Wildlife

INVENTOR(S): DIETZSCHOLD, Bernhard, HOOPER, D. Craig,
SCHNELL, Matthias

"Express Mail" Label No. ET601501092US
Date of Deposit – July 27, 2001

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Commissioner of
Patents and Trademarks, Washington, D.C. 20231.

By

A handwritten signature in black ink that appears to read "Janet B. Smith".

Typed Name: Janet B. Smith

Box Missing Parts
Commissioner of Patents & Trademarks
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

O P E

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/816,531	JUL 27 2001 2001 PATENT & TRADEMARK OFFICE	Bernhard Dietzschold	DIE01-NP001

JUL 27 2001
2001
PATENT & TRADEMARK OFFICE

24358
 CLIFFORD K. WEBER, ESQ
 OFFICE OF UNIVERSITY COUNSEL, THOMAS JEFFERSON UNI
 1020 WALNUT STREET
 SUITE 620
 PHILADELPHIA, PA 19107

CONFIRMATION NO. 8032
 CORRECTION COVER LETTER




OC000000006327295

Date Mailed: 07/23/2001

COVER LETTER FOR CORRECTION OF PREVIOUS NOTICE

The Notice mailed on 04/27/2001 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.




hus
A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILED/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/816,531	03/23/2001	Bernhard Dietzschold	DIE01-NP001



JUL 27 2001
USPTO
U.S. PATENT & TRADEMARK OFFICE

CONFIRMATION NO. 8032

24358

CLIFFORD K. WEBER, ESQ.
 OFFICE OF UNIVERSITY COUNSEL, THOMAS JEFFERSON UNI
 1020 WALNUT STREET
 SUITE 620
 PHILADELPHIA, PA 19107

FORMALITIES LETTER



OC000000006327318

Date Mailed: 07/23/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE